Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Ultragenyx (NASDAQ: RARE) announced an inducement equity grant under Nasdaq Listing Rule 5635(c)(4).
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Ultragenyx (NASDAQ: RARE) announced an inducement equity grant under Nasdaq Listing Rule 5635(c)(4). The company granted 16,355 restricted stock units to nine newly hired non-executive officers, approved by the compensation committee and issued under the Ultragenyx Employment Inducement Plan.
The grants have a grant date of January 16, 2026 and vest over four years with 25% of the underlying shares vesting on each anniversary of the grant date, subject to continued employment as of each vesting date.
Details
News Market Reaction – RARE
On Jan 26, the first trading day after this news, RARE closed 0.41% above the previous close.
Data tracked by StockTitan Argus for the Jan 26 session.
Key Figures
- Inducement RSUs
- 16,355 units
- Granted to nine newly hired non-executive officers
- Employees granted
- 9 employees
- Recipients of inducement restricted stock units
- Grant date
- January 16, 2026
- RSU grant date under Ultragenyx Employment Inducement Plan
- Vesting period
- 4 years
- RSUs vest over four years subject to continued employment
- Annual vesting rate
- 25% per year
- 25% of shares vest on each grant-date anniversary
Historical Context
-
Preliminary 2025 revenue growth and multiple 2026 regulatory and clinical catalysts outlined.
-
Announcement of J.P. Morgan Healthcare Conference presentation and webcast access details.
-
Completion of DTX401 BLA supported by data from 52 treated patients over six years.
-
Orbit and Cosmic trials missed primary fracture endpoint despite BMD gains and stable safety.
-
Grant of 13,144 RSUs to new non-executive officers under inducement plan.
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Key Terms
restricted stock units financial
nasdaq listing rule 5635(c)(4) regulatory
AI-generated analysis. How Rhea-AI works. Not financial advice.
NOVATO, Calif., Jan. 23, 2026 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development and commercialization of novel therapies for rare and ultra-rare diseases, today reported the grant of 16,355 restricted stock units of the company’s common stock to nine newly hired non-executive officers of the company. The awards were approved by the compensation committee of the company’s board of directors and granted under the Ultragenyx Employment Inducement Plan, with a grant date of January 16, 2026, as an inducement material to the new employees entering into employment with Ultragenyx in accordance with Nasdaq Listing Rule 5635(c)(4).
The restricted stock units vest over four years, with
About Ultragenyx Pharmaceutical Inc.
Ultragenyx is a biopharmaceutical company committed to bringing novel products to patients for the treatment of serious rare and ultrarare genetic diseases. The company has built a diverse portfolio of approved therapies and product candidates aimed at addressing diseases with high unmet medical need and clear biology for treatment, for which there are typically no approved therapies treating the underlying disease.
The company is led by a management team experienced in the development and commercialization of rare disease therapeutics. Ultragenyx’s strategy is predicated upon time- and cost-efficient drug development, with the goal of delivering safe and effective therapies to patients with the utmost urgency.
For more information on Ultragenyx, please visit the company's website at: www.ultragenyx.com.
Contact Ultragenyx
Investors & Media
Joshua Higa
(415) 475-6370
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.